Monoclonal antibodies for the immunotherapy of solid tumours

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1385-1398

  Mauerer, Richard ^a   Gruber, Rudolf ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antibody dependent cell cytotoxicity (ADCC); Complementmediated lysis; Micro metastasis; Tumour associated antigen (TAA); Tumour infiltrating lymphocytes (TIL)

Indexed keywords

ADECATUMUMAB; BEVACIZUMAB; CATUMAXOMAB; CETUXIMAB; CIXUTUMUMAB; FIGITUMUMAB; HECEPTIN; IPILIMUMAB; LEXATUMUMAB; MAPATUMUMAB; MONOCLONAL ANTIBODY; PANITUMUMAB; PRITUMUMAB; TICILIMUMAB; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; ARTICLE; BIOLOGICAL ACTIVITY; BONE MARROW METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CANCER; COLON METASTASIS; COLORECTAL CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT ASCITES; MELANOMA; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXYGEN SUPPLY; PANCREAS CANCER; PROSTATE CANCER; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84860520991     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784844     Document Type: Article

References (80)

1. Schlimok, G.; Funke, I.; Holzmann, B.; Göttlinger, G.; Schmitdt, G.; Häuser, H.; Swierkot, S.; Warnecke, H.H.; Schneider, B.; Koprowski, H.; Riethmüller, G. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Medical Sciences, 1987, 84 (12), 8672-8676.
2. Holmgren, L.; O'Reilly, M.; Folkman, J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1995, 1, 149-53.
3. Reichert, J.M. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol., 2008, 9 (6), 423-30.
4. Beck, A.; Wurch, T.; Corvaia, N. Therapeutic antibodies and derivatives: from the bench to the clinic. Curr. Pharm. Biotechnol., 2008, 9 (6), 421-2.
5. Schadendorf, D.; Algarra, S.M.; Bastholt, L.; Cinat, G.; Dreno, B.; Eggermont, A.M.; Espinosa, E.; Guo, J.; Hauschild, A.; Petrella, T.; Schachter, J.; Hersey, P. Immunotherapy of distant metastatic disease. Ann. Oncol., 2009, 20 Suppl 6, vi41-50.
6. Ribas, A.; Hanson, D.C.; Noe, D.A.; Millham, R.; Guyot, D.J.; Bernstein, S.H.; Canniff, P.C.; Sharma, A.; Gomez-Navarro, J. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. The Oncologist, 2007, 12 (7), 873-883.
7. Hodi, F.S.; Butler, M.; Oble, D.A.; Seiden, M.V.; Haluska, F.G.; Kruse, A.; Macrae, S.; Nelson, M.; Canning, C.; Lowy, I.; Korman, A.; Lautz, D.; Russell, S.; Jaklitsch, M.T.; Ramaiya, N.; Chen, T.C.; Neuberg, D.; Allison, J.P.; Mihm, M.C.; Dranoff, G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Nat. Acad. Sci. U.S.A., 2008, 105 (8), 3005-3010.
8. Yang, Y.F.; Zou, J.P.; Mu, J.; Wijesuriya, R.; Ono, S.; Walunas, T.; Bluestone, J.; Fujiwara, H.; Hamaoka, T. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer res., 1997, 57 (18), 4036-4041.
9. Meyerhardt, J.A.; Mayer, R.J. Systemic therapy for colorectal cancer. The New Eng. J. Med., 2005, 352 (5), 476-487.
10. Zitvogel, L.; Tesniere, A.; Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nature Rev., 2006, 6 (10), 715-727.
11. Stewart, T.; Tsai, J.; Greyson, H.; Henderson, R.; Opelz, G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet, 1995, 346, 796-798.
12. Curtis, R.E.; Rowlings, P.A.; Deeg, H.J.; Shriner, D.A.; Socie, G.; Travis, L.B.; Horowitz, M.M.; Witherspoon, R.P.; Hoover, R.N.; Sobocinski, K.A.; Fraumeni, J.F.Jr.; Boice, J.D.Jr. Solid cancers after bone marrow transplantation [see comments]. The New Engl. J. Med., 1997, 336 (13), 897-904.
13. Gallucci, S.; Matzinger, P. Danger signals: SOS to the immune system. Curr. opin. immuno., 2001, 13 (1), 114-119.
14. Aggarwal, S. What's fueling the biotech engine--2008. Nat. biotechnol., 2009, 27 (11), 987-993.
15. Chartrain, M.; Chu, L. Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies. Curr. Pharm. Biotechnol., 2008, 9 (6), 447-467.
16. Beck, A.; Wagner-Rousset, E.; Bussat, M.C.; Lokteff, M.; Klinguer-Hamour, C.; Haeuw, J.F.; Goetsch, L.; Wurch, T.; Van Dorsselaer, A.; Corvaia, N. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr. Pharm. Biotechnol., 2008, 9 (6), 482-501.
17. Dove, A. Antibody production branches out. Nat. Methods, 2009, 6 (11), 851-855.
18. Ravetch, J. Fc Receptors: Rubor redux. Cell, 1994, 78, 553-560.
19. Nimmerjahn, F.; Ravetch, J.V. Fcgamma receptors as regulators of immune responses. Nat. Reviews, 2008, 8 (1), 34-47.
20. Gruber, R. Neue Diagnose- und Therapie-Ansätze bei Tumoren. Diagnostica Dialog, 1998, 1, 7-9.
21. Rosenberg, S.A. Principles and applications of biologic therapy. In Cancer: Principles and practice of oncology, 4th ed.; DeVita, V. T.; Hellman, S.; Rosenberg, S. A., Eds. J.B. Lippincott Co.: Philadelphia, 1993; pp 293-324.
22. Jager, D. Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). Methods Mol. Biol., 2007, 360, 319-326.
23. Saga, T.; Neumann, R.; Heya, T.; Sato, J.; Kinuya, S.; Le, N.; Peik, C.; Weinstein, J. Targeting cancer micrometastases with monoclonal antibodies: A binding-site barrier. Proc. Natl. Acad. Sci., 1995, 92, 8999-9003.
24. Shen, J.-W.; Atkinson, B.; Koprowski, H.; Sears, H., Binding of murine immunoglobulin to human tissues after immunotherapy with anticolorectal carcinoma monoclonal antibody. Int J Cancer, 1984, 33, 465-468.
25. Shetye, J.; Frödin, J.-E.; Christensson, B.; Grant, C.; Jacobsson, B.; Sundelius, S.; Sylven, M.; Biberfeld, P.; Mellstedt, H., Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A). Cancer Immunol. Immunother., 1988, 27, 154-162.
26. Gruber, R.; Fackler-Schwalbe, I.; Schlimok, G.; Pantel, K.; Riethmüller, G. In Immunohistochemical detection of in vivo binding of therapeutic monoclonal antibodies (17-1A, LeY) in metastatic colorectal cancer patients, 1st Int. Meeting on Minimal residual cancer, Munich, Germany, 1996.
27. Gruber, R.; Holz, E.; Riethmüller, G. Monoclonal antibodies in cancer therapy. Springer Semin Immunopathol., 1996, 18, 243-251.
28. Khazaeli, M.; Conry, R.; LoBuglio, A. Human Immune Response to monoclonal antibodies. J. Immunother., 1994, 15, 42-52.
29. Herlyn, D.; Harris, D.; Zaloudik, J.; Sperlagh, M.; Maruyama, H.; Jacob, L.; Kieny, M. P.; Scheck, S.; Somasundaram, R.; Hart, E., Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients. J. Immunother. Emphasis Tumor Immunol., 1994, 15 (4), 303-311.
30. Shoenfeld, Y.; Amital, H.; Ferrone, S.; Kennedy, R. Anti-idiotypes and their application under autoimmune, neoplastic, and infectious conditions. Int. Arch. Allergy Immmunol., 1994, 105, 211-223.
31. Herlyn, D.; Wettendorff, M.; Schmoll, E.; Iliopoulos, D.; Schedel, I.; Dreikhausen, U.; Raab, R.; Ross, A. H.; Jaksche, H.; Scriba, M. Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc. Natl. Acad. Sci. of U. S. A., 1987, 84 (22), 8055-8059.
32. HAMA Survey Group, Survey of methods for measuring human anti-mouse antibodies. Clin. Chim. Acta., 1993, 215 (2), 153-163.
33. Conry, R. M.; Khazaeli, M. B.; LoBuglio, A. F. Lack of T-cell immunity in humans with preexisting anti-mouse immunoglobulin reactivity. Cancer Research, 1992, 52 (24), 6979-6982.
34. Reinsberg, J. Interference by human antibodies with tumor marker assays. Hybridoma, 1995, 14 (2), 205-208.
35. Hasholzner, U.; Stieber, P.; Meier, W.; Lamerz, R. Value of HAMA--determination in clinical practice--an overview. Anticancer Res., 1997, 17 (4b), 3055-3058.
36. Reinsberg, J. Interferences with two-site immunoassays by human anti-mouse antibodies formed by patients treated with monoclonal antibodies: comparison of different blocking reagents. Clin. Chem., 1998, 44 (8 Pt 1), 1742-1744.
37. Melton, R.; Sherwood, R. Antibody-enzyme conjugates for cancer therapy. J. Natl. Cancer Inst., 1996, 88, 153-165.
38. Knox, S. Overview of studies on experimental radioimmunotherapy. Canc. Res., 1995, 55, 5832s-5836s (Suppl).
39. Velders, M. P.; van Rhijn, C. M.; Oskam, E.; Fleuren, G. J.; Warnaar, S. O.; Litvinov, S. V. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. British J. Canc., 1998, 78 (4), 478-483.
40. Rheinnecker, M.; Hardt, C.; Ilag, L. L.; Kufer, P.; Gruber, R.; Hoess, A.; Lupas, A.; Rottenberger, C.; Pluckthun, A.; Pack, P. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. J. Immunol., 1996, 157 (7), 2989-2997.
41. Buist, M. R.; Kenemans, P.; van Kamp, G. J.; Haisma, H. J. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol. Immunother., 1995, 40 (1), 24-30.
42. Winter, G. Synthetic human antibodies and a strategy for protein engineering. FEBS lett., 1998, 430, 92-94.
43. Welt, S. In Study of humanized A33 antibody in patients with advanced colorectal cancer, Antibodies 1998: Molecular, Cellular & Clinical Aspects, New York, New York, 1998.
44. Griffiths, A.; Williams, S.; Hartley, O.; Tomlinson, I.; Waterhouse, P.; Crosby, W.; Kontermann, R.; Jones, P.; Low, N.; Allison, T. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J., 1994, 13, 3245-3260.
45. Thie, H.; Meyer, T.; Schirrmann, T.; Hust, M.; Dubel, S. Phage display derived therapeutic antibodies. Curr. Pharm. Biotechnol., 2008, 9 (6), 439-446.
46. Raum, T.; Gruber, R.; Riethmüller, G.; Kufer, P. In A human 17- 1A antibody for the treatment of minimal residual colorectal carcinomas, selected from a combinatorial human IgD library, Antibody Engineering, San Diego, San Diego, 1997.
47. Mack, M.; Gruber, G.; Schmidt, S.; Riethmüller, G.; Kufer, P. Biologic Properties of a Bispecific Single-Chain Antibody Directed Against 17-1A (EpCAM) and CD3. J. Immunol., 1997, 158, 3965-3970.
48. Anonymous Monoclonal Antibodies. http://en.wikipedia.org/wiki/Monoclonal_antibody#Applications
49. DeVita, V. T.; Hellman, S.; Rosenberg, S. A. Biologic therapy of cancer. 2nd ed.; J.B. Lippincott Co.: Philadelphia, 1995.
50. Fields, A. L.; Keller, A.; Schwartzberg, L.; Bernard, S.; Kardinal, C.; Cohen, A.; Schulz, J.; Eisenberg, P.; Forster, J.; Wissel, P. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J. Clin. Oncol., 2009, 27 (12), 1941-1947.
51. Hudis, C. A. Trastuzumab--mechanism of action and use in clinical practice. The New Engl. J. Med., 2007, 357 (1), 39-51.
52. Smith, I.; Procter, M.; Gelber, R. D.; Guillaume, S.; Feyereislova, A.; Dowsett, M.; Goldhirsch, A.; Untch, M.; Mariani, G.; Baselga, J.; Kaufmann, M.; Cameron, D.; Bell, R.; Bergh, J.; Coleman, R.; Wardley, A.; Harbeck, N.; Lopez, R. I.; Mallmann, P.; Gelmon, K.; Wilcken, N.; Wist, E.; Sanchez Rovira, P.; Piccart-Gebhart, M. J. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 2007, 369 (9555), 29-36.
53. Van Cutsem, E.; Kohne, C. H.; Hitre, E.; Zaluski, J.; Chang Chien, C. R.; Makhson, A.; D'Haens, G.; Pinter, T.; Lim, R.; Bodoky, G.; Roh, J. K.; Folprecht, G.; Ruff, P.; Stroh, C.; Tejpar, S.; Schlichting, M.; Nippgen, J.; Rougier, P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New Engl. J. Med., 2009, 360 (14), 1408-1417.
54. Freeman, D. J.; Bush, T.; Ogbagabriel, S.; Belmontes, B.; Juan, T.; Plewa, C.; Van, G.; Johnson, C.; Radinsky, R. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol. Cancer Therapeutics, 2009, 8 (6), 1536-1546.
55. Martinelli, E.; De Palma, R.; Orditura, M.; De Vita, F.; Ciardiello, F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin. exp. immunol., 2009, 158 (1), 1-9.
56. Ogino, S.; Meyerhardt, J. A.; Irahara, N.; Niedzwiecki, D.; Hollis, D.; Saltz, L. B.; Mayer, R. J.; Schaefer, P.; Whittom, R.; Hantel, A.; Benson, A. B., 3rd; Goldberg, R. M.; Bertagnolli, M. M.; Fuchs, C. S. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin. Cancer Res., 2009, 15 (23), 7322-7329.
57. Van Cutsem, E.; Peeters, M.; Siena, S.; Humblet, Y.; Hendlisz, A.; Neyns, B.; Canon, J.L.; Van Laethem, J.L.; Maurel, J.; Richardson, G.; Wolf, M.; Amado, R.G. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol., 2007, 25 (13), 1658-1664.
58. Sebastian, M.; Kiewe, P.; Schuette, W.; Brust, D.; Peschel, C.; Schneller, F.; Ruhle, K.H.; Nilius, G.; Ewert, R.; Lodziewski, S.; Passlick, B.; Sienel, W.; Wiewrodt, R.; Jager, M.; Lindhofer, H.; Friccius-Quecke, H.; Schmittel, A. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. J. Immunother., 2009, 32 (2), 195-202.
59. Widakowich, C.; Dinh, P.; de Azambuja, E.; Awada, A.; Piccart- Gebhart, M. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? Anti-Cancer Agents Med. Chem., 2008, 8 (5), 488-496.
60. Dinh, P.; de Azambuja, E.; Piccart-Gebhart, M.J. Trastuzumab for early breast cancer: current status and future directions. Clin. Adv. Hematol. Oncol., 2007, 5 (9), 707-717.
61. van Elsas, A.; Hurwitz, A.A.; Allison, J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)- producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med., 1999, 190 (3), 355-366.
62. Kirman, I.; Whelan, R.L. Drug evaluation: adecatumumab, an engineered human anti-EpCAM antibody. Curr. Opin. Mol. Ther., 2007, 9 (2), 190-196.
63. Oberneder, R.; Weckermann, D.; Ebner, B.; Quadt, C.; Kirchinger, P.; Raum, T.; Locher, M.; Prang, N.; Baeuerle, P.A.; Leo, E. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur. J. Cancer, 2006, 42 (15), 2530-2538.
64. Schmidt, M.; Scheulen, M.E.; Dittrich, C.; Obrist, P.; Marschner, N.; Dirix, L.; Schmidt, M.; Ruttinger, D.; Schuler, M.; Reinhardt, C.; Awada, A. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann. Oncol., 2009.
65. McKian, K.P.; Haluska, P. Cixutumumab. Expert Opin. Investig. Drugs. 2009, 18 (7), 1025-1033.
66. Gualberto, A.; Karp, D.D. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin. Lung Cancer, 2009, 10 (4), 273-280.
67. Haluska, P.; Worden, F.; Olmos, D.; Yin, D.; Schteingart, D.; Batzel, G. N.; Paccagnella, M. L.; de Bono, J. S.; Gualberto, A.; Hammer, G. D. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother. Pharmacol., 2010, 65(4):765-773
68. Karp, D.D.; Paz-Ares, L.G.; Novello, S.; Haluska, P.; Garland, L.; Cardenal, F.; Blakely, L.J.; Eisenberg, P.D.; Langer, C.J.; Blumenschein, G. Jr.; Johnson, F.M.; Green, S.; Gualberto, A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J. Clin. Oncol., 2009, 27 (15), 2516-2522.
69. Wakelee, H.A.; Patnaik, A.; Sikic, B.I.; Mita, M.; Fox, N.L.; Miceli, R.; Ullrich, S.J.; Fisher, G.A.; Tolcher, A.W. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann. Oncol., 2010, 21(2):376-381
70. Leong, S.; Cohen, R.B.; Gustafson, D.L.; Langer, C.J.; Camidge, D.R.; Padavic, K.; Gore, L.; Smith, M.; Chow, L. Q.; von Mehren, M.; O'Bryant, C.; Hariharan, S.; Diab, S.; Fox, N.L.; Miceli, R.; Eckhardt, S.G. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J. Clin. Oncol., 2009, 27 (26), 4413-4421.
71. Glassy, M.C.; Hagiwara, H. Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab. Human Antibodies, 2009, 18 (4), 127-137.
72. Graziano, F.; Ruzzo, A.; Loupakis, F.; Canestrari, E.; Santini, D.; Catalano, V.; Bisonni, R.; Torresi, U.; Floriani, I.; Schiavon, G.; Andreoni, F.; Maltese, P.; Rulli, E.; Humar, B.; Falcone, A.; Giustini, L.; Tonini, G.; Fontana, A.; Masi, G.; Magnani, M. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J. Clin. Oncol., 2008, 26 (9), 1427-1434.
73. Yan, L.; Beckman, R.A. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. BioTechniques, 2005, 39 (4), 565-568.
74. Braun, S.; Pantel, K.; Muller, P.; Janni, W.; Hepp, F.; Kentenich, C.R.; Gastroph, S.; Wischnik, A.; Dimpfl, T.; Kindermann, G.; Riethmuller, G.; Schlimok, G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer [see comments]. N. Engl. J. Med., 2000, 342 (8), 525-533.
75. Janni, W.; Gastroph, S.; Hepp, F.; Kentenich, C.; Rjosk, D.; Schindlbeck, C.; Dimpfl, T.; Sommer, H.; Braun, S. Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma. Cancer, 2000, 88 (10), 2252-2259.
76. Fogler, W.E.; Klinger, M.R.; Abraham, K.G.; Gottlinger, H.G.; Riethmüller, G.; Daddona, P.E. Enhanced cytotoxicity against colon carcinoma by combinantions of noncompeting monoclonal antibodies to the 17-1A antigen. Cancer Res., 1988, 48, 6303-6308.
77. Saleh, M.; Khazaeli, M.; Wheeler, R.; Bucy, R.; Liu, T.; Everson, M.; Munn, D.; Schlom, J.; LoBuglio, A. Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rh-M-CSF) in patients with metastatic gastrointesinal cancer. Cancer Res., 1995, 55, 4330-4346.
78. Amann, M.; D'Argouges, S.; Lorenczewski, G.; Brischwein, K.; Kischel, R.; Lutterbuese, R.; Mangold, S.; Rau, D.; Volkland, J.; Pflanz, S.; Raum, T.; Munz, M.; Kufer, P.; Schlereth, B.; Baeuerle, P. A.; Friedrich, M. Antitumor activity of an EpCAM/CD3- bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J. Immunother., 2009, 32 (5), 452-64.
79. Baeuerle, P.A.; Kufer, P.; Bargou, R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr. Opin. Molecular Ther., 2009, 11 (1), 22-30.
80. Nagorsen, D.; Bargou, R.; Ruttinger, D.; Kufer, P.; Baeuerle, P. A.; Zugmaier, G. Immunotherapy of lymphoma and leukemia with Tcell engaging BiTE antibody blinatumomab. Leukemia & Lymphoma, 2009, 50 (6), 886-891.